Reversing the downward trend has not happened, is the market mistaking in its view that $25.00 may be the next value of a share, perhaps the 90 day Rx refill program earnings will show a short term upward trend.
In analysing Managements performance on the margin of profit of it's core earnings, it has not satisfied wallstreet investors, just look at the daily volume and price. The measure of core growth has not occured with out buying patient files and the D/R revenue, combinding revenue is not the same as growing it. This is sign of weakness in the company's position in this sector and should be of matter of concern to the Board of Directors.
I see no rationalization of managements compensation on preformance.. when core objective are not achieved and SG&A is not being addressed..
Perhaps some of "there is a way" stockholders could share their insite.